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BACKGROUND: Inflammation is one of the factors that associated with insulin resistance which causes type 2 diabetes mellitus (T2DM). Inflammation can 
be measured by using high sensitivity C-reactive protein (hs-
CRP), a quantitative measurement of CRP concentration. 
Puguntano is a plant that traditionally used for antidiabetic 
treatment found in North Sumatera. The objective of this 
study is to know the effect of Puguntano extract on hs-CRP 
level in newly diagnosed T2DM patient.
METHODS: The study was a randomized controlled 
clinical trial on 24 newly diagnosed T2DM patients. 
Subjects were divided into 2 groups. The first group was 
given Puguntano extract with starting doses at 100 mg daily, 
then the dose was increased in titration up to a  maximum 
dose of 2x100 mg daily depending on blood sugar level 
monitoring. Meanwhile, the other group (which serves as 
a control group) was given metformin with starting doses 
at 500 mg daily, then the dose was increased in titration 
up to a maximum dose of 3x500 mg per day depending on 
blood sugar level monitoring. The hs-CRP and HbA1c are 
assessed at the baseline and after 12 weeks of treatment.
RESULTS:  The hs-CRP level was decreased in Puguntano 
group by 1.41 (-7.54-0.52) (p=0.06) and decrease by 0.58 
(-7.86-33.41) (p=0.695) in metformin group. There was 
no difference in hs-CRP level between the two groups 
(p=0.630).
CONCLUSION: Puguntano extract showed the effect 
of lowering HbA1C and hs-CRP level in T2DM patients, 
although it was not statistically significant.
KEywORDS:  type  2  diabetes  mellitus,   hs-CRP, 
puguntano
Indones Biomed J. 2018; 10(1): 79-83
Abstract
Introduction
Diabetes mellitus (DM) is a group of chronic metabolic 
diseases and a severe problem in the community. Although 
there are many pathogenic factors involved in type 2 DM 
(T2DM), it is quite difficult to estimate which type of 
mechanism is involved in different tissues. Nevertheless, it 
is still noteworthy that all these cellular stress mechanisms 
are considered to overlap with each other and provoke 
inflammation in pancreatic tissues.(1-3)  
  One of the markers that can be used to measure 
inflammation is C-reactive protein (CRP). CRP examination 
can detect acute inflammation and severe tissue damage. 
High sensitivity CRP (hs-CRP) is a quantitative measure of 
CRP concentrations which can measure levels up to <0.2 
mg/L.(4)
 Pick Up, et al., suggested an increased attention to 
the involvement of chronic low-grade inflammation and 
activation of the innate immune system in the pathogenesis 
of T2DM. CRP is an inflammatory marker that is produced 
and released by the liver under the influence of cytokines 
such as tumor necrosis factor (TNF), interleukin (IL)-1 
and IL-6.(5) Some prospective studies have suggested that 
increased CRP level is associated with an increased risk of 
T2DM.(6)
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 Puguntano (Curanga fel-terrae Merr), a medicinal 
plant from Scrophulariaceae family, grows in Asia, 
especially in China, India, Indonesia, Philippines, Malaysia 
and Myanmar. In Indonesia, people in Tiga Lingga Village, 
Dairi district, North Sumatera, has traditionally used 
Puguntano leaves as an antidiabetic treatment. This plant is 
also believed to be effective in relieving pain, increasing 
endurance, or even used for anti-aging. This plant has now 
been started to be cultivated by the local community as a 
medicinal plant.
 One study shows that ethanol extract of Puguntano 
leaf has a potential effect as an anti-inflammatory.(7) On 
the other hand, another  study  has  conducted  a  clinical 
trial and reported that Puguntano leaf, Simplicia powder, 
has an effect in lowering blood sugar levels in patients with 
diabetes mellitus, if given orally with the dose of 2 gram 
steeped in water, 3 times a day, for 14 days.(8)  Based on the 
background above, the aim of this study is to investigates 
the effect of Puguntano extract in decreasing the hs-CRP 
level in T2DM patients. 
Methods
Consecutive random sampling was used to select newly 
diagnosed T2DM subjects, and the study was double-blind 
to the assigned treatment. Subjects were provided with 
the information regarding the study, and those agreeing to 
participate filled the written informed consent. The study 
was conducted in the outpatient clinic of Haji Adam Malik 
General Hospital, Medan, from February to July 2016. The 
study protocol was approved by the ethics committee of 
Faculty of Medicine, University of Sumatera Utara (Ethical 
No.: 83/KOMET/FK USU/2016). The study was conducted 
in accordance with good clinical practice (GCP) and all 
applicable required regulation. Inclusion criteria were male 
and female patients, whose age above 17 years, newly 
diagnosed T2DM and willing to fill the written consent 
voluntary prior to the study. T2DM was diagnosed based on 
American Diabetes Association (ADA) and The Indonesian 
Society of Endocrinology (Perkumpulan Endokrinologi 
Indonesia/PERKENI) criteria.(15,16) The exclusion 
criteria were patient with anemia (for male Hb <12 g/dL or 
female Hb <11g/dL), hypertension (systolic blood pressure 
≥140 mmHg and/or diastolic blood pressure ≥90 mmHg), 
impaired renal function (creatinin >2mg/dL) and hepatic 
function (SGOT/SGPT >2x upper normal limit, severe 
infection  and  did  not complied with research procedure 
(drop out). 
 Anamnesis was performed to obtain demographic data 
(include age and sex), height, weight, waist circumference, 
history of diabetes mellitus, history of smoking, family 
history of the disease, history of hypertension and previous 
laboratory examination. Blood collection was performed 
after 10-12 hours fasting for laboratory assessment. All 
eligible subjects then randomly devided into treatment 
groups (which treated with Puguntano extract) and control 
groups (treated with metformin) by simple random sampling. 
All subjects in the treatment group were given Puguntano 
with starting doses at 100 mg daily. Blood sugar level 
was monitored using glucose dipsticks weekly. When DM 
target therapy had been achieved, the dose was maintained, 
whereas if the target had not been reached then dose was 
increased in titration up to a maximum dose of 2x100 
mg daily. All subjects in the metformin group were given 
metformin with starting doses at 500 mg daily. Blood sugar 
levels also monitored weekly using dipstick. When DM 
target therapy had been achieved, the dose was maintained, 
whereas if the target had not been achieved then the dose was 
increased in titration up to a maximum dose of 3x500 mg 
per day. Interventions for both groups were conducted for 
12 weeks. All subjects were monitored by checking blood 
sugar weekly at the endocrinology metabolic outpatient 
clinic Haji Adam Malik Hospital, Medan, and each patient 
was also given a telephone number that can be contacted, in 
case any side effects shows up.
 For both groups of patients, blood samples were taken 
in the cubital fossa area for examination of hs-CRP levels at 
the baseline and after 12 weeks of treatment. The hs-CRP 
was examined by using immunoturbidimetri method with 
architect i system tools at Prodia Laboratory in S. Parman, 
Medan, North Sumatera.
 Puguntano extract was made by percolation method 
using 70% ethanol solvent. A 300 gram of Simplicia powder 
was incorporated into a lid and moistened with 50% ethanol 
liquid, macerated for 3 hours. The mass was transferred bit 
by bit into the percolator, and then the liquid of the pellet 
was poured sufficiently until there was a layer of liquid of 
the dancer above the Simplicia and left for 24 hours. The 
liquid was allowed to drip at a rate of 1 mL per minute, 
the liquid was repeatedly added so that there is always a 
layer of liquid on the Simplicia, percolation was stopped 
until the last polishing out was not colored. Percolate was 
concentrated by using rotavapor, after the thick extract was 
obtained, then it was dried in a freeze dryer. 
 Puguntano leaf extract was at doses of 100 mg and 
mixed with fillers until the capsule weight of 500 mg 
used capsule shell number 0. Puguntano leaf extract was 
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condensed gradually with filler and drier (amylum manihot 
5%, amylum maydis 2.5% and lactic saccharin) to obtain a 
compact mass, then made granules by sieving the mass. It 
was dried in the drying cupboard for 1 hour to obtain dry 
granules, and was being rejuvenated and mixed with lactic 
saccharum until it reaches the appropriate weight. Then it 
was inserted into capsule shell with the aid of capsule filler.
 Tabulation was used to show the descriptive 
characteristics of subjects. Shapiro-wilk analysis was 
performed to assess the normality of data. Wilcoxon analysis 
was performed to assess the differences between each group. 
Mann Whitney analysis was used to assess the differences 
between intergroup. Data were processed and analyzed by 
using SPSS 22.0 for windows (SPSS Inc, Chicago, USA), 
with significance level of p<0,05.Results
Total 24 subjects of T2DM were recruited and met the 
eligibility. The subjects randomly assigned into two groups, 
12 subjects in each group. Baseline characteristics of the 
subjects in this study are shown in Table 1. Baseline values 
of all measured parameters were comparable between 
Puguntano and metformin group.
 Shapiro-wilk analysis was performed to assess 
the normality of data. Because the data do not normally 
distributed, comparative analysis for each group was 
performed wiith wilcoxon analysis. Meanwhile to assess the 
Puguntano,
Median (IQR)
Metformin, 
Median (IQR) p
Male 3 4
 Female 9 8
56.5 (47-60) 52.5 (40-59) 0.177
Body weight (kg) 62.5 (41-75) 63.25 (41-70) 0.594
Body height (cm) 157.5(148-165) 156 (150-170) 0.787
BMI (kg/m2) 25.4 (17-31.2) 24.7 (17-28.9)) 0.811
Waist circumference (cm) 93.50 (88-103) 94 (89-104) 0.664
Fasting blood sugar (mg/dL) 223.17(112-310) 169.17 (89-349) 0.299
2 hours post-prandial blood sugar (mg/dL)    301(124-410) 263 (82-449) 0.391
HbA1c (%) 9.65 (6.10-17.5) 8.92 (6.10-11.8) 0.356
hs-CRP (mg/dL) 2.7 (0.2-9.63) 2.87 (0.6-9-94) 0.371
Characteristics
Sex
Age (years)
Anthropometry
Glucose status    
Table 1. Baseline characteristics of subjects. 
differences between intergroup, Mann Whitney analysis was 
performed. Table 2 shows that subjects receiving Puguntano 
extract have significant differences of fasting blood sugar 
and HbA1c levels before and after treatment (p<0.05). 
While hs-CRP levels showed a decrease 1.41 (-7.54-0.52), 
from 2.79 (0.2-9.63) before the treatment and 1.28 (0.24-
3.3) after treatment. However, using the Wilcoxon test, no 
significant difference was found between before and after 
treatment (p=0.06).
 In the subjects receiving metformin, fasting blood 
glucose and HbA1c level showed significant differences 
between before and after metformin (p<0.05). While on 
hs-CRP, the hsCRP level was decreased 0.58 (-7.86-33.41) 
from 2.87 (0.6-9.94) before treatment and 2.29 (1.01-36.97) 
after treatment. Based on Wilcoxon test, no significant 
difference was found (p=0.695).Discussion
The use of traditional medicine continues to grow rapidly 
in the community. This is supported by various factors and 
issues that develop at this time in the attitude back to nature. 
The utilization of traditional medicine in various regions 
is hereditary heritage based on experience/empirical then 
developed through scientific proof through pre-clinical 
test and clinical trials.(9) Puguntano (Curanga fel-terrae 
(Lour.) Merr.) often called Picria fel-terrae is a plant of 
the Scrophulariaceae family that grows in Asia, especially 
IQR: Interquartile range
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Before, After, Before, After,
Median (IQR) Median (IQR) Median (IQR) Median (IQR)
Fasting blood sugar 
(mg/dL)
223.17 (112-310) 165.50 (102-196) 57.67 (-24-228) 0.012* 169.17 (89-349) 127.50 (74-187) 41.67  (-22-93) 0.010* 0.773
2 hours post-prandial 
blood sugar (mg/dL)
301.25 (124-410) 276.25 (120-441) 25.00 (-211-200) 0.480 251.83 (82-449) 245.00 (76-354) 6.83 (-214-162) 0.875 0.862
HbA1c (%) 9.65 (6.10-17.5) 8.13 (6.20-12.1) 1.53 (-1.8-6.1) 0.022* 8.92 (6.10-11.8) 7.44 (6.10-10.3) 1.48 (-1.8-6.1) 0.012* 0.686
hs-CRP (mg/L) 2.79 (0.2-9.63) 1.28 (0.24-3.3) 1.41 (-7.54-0.52) 0.060 2.87 (0.6- 9.94) 2.29 (1.01-36.97) 0.58 (-7.86-33.41) 0.695 0.630
p cVariable
Puguntano Metformin
p a p bΔ Δ
Table 2. Comparison of HbA1c parameters, fasting blood sugar, 2 hours post-prandial blood sugar, hs-CRP between before and 
after Puguntano and metformin interventions for 12 weeks.
Δ : difference before and after intervention  
pa: p value difference between before and after (Puguntano group), analyzed by Wilcoxon test
pb: p value difference between before and after (metformin group), analyzed by Wilcoxon test
pc: p value difference between Puguntano and  metformin group, analyzed by Mann-Whitney test
*Significant
in China, India, Indonesia, Philippines, Malaysia, and 
Myanmar. In Indonesia, this plant is spread in Sumatra, Java, 
Kalimantan and Maluku. Various studies were conducted to 
determine the chemical compounds and potential usefulness 
for health from Puguntano.
 One study found a decrease in the inflammatory 
marker (hs-CRP) in T2DM patients in the Puguntano group 
after 12 weeks of treatment although this decrease was 
not statistically significant. Another study mentioned that 
ethanol extract from Puguntano leaf at 10 mg/kg of body 
weight which is given orally in male mice, has similar 
anti-inflammatory effect with 10mg/kg of body weight 
indomethacin against artificial inflammation induced by 1% 
λ-carragenan solution intraplantar.(7) The n-hexane extract 
was obtained from leaf Picria fel-terrae lour has the ability 
to decrease blood glucose level by 44.47% in mice after 
10 days treatment, which is compared the administration 
of n-hexane isolated from Puguntano at dose 200 mg/kg 
of body weight and metformin at dose 50 mg/kg of body 
weight in mice. They  found no significant reduction on 
day 10 with 135 mg/dL (±11.35) of 447.17 mg/dL (±6.92) 
in the metformin group and 167 mg/dL (±4.76) from 513 
mg/dL (±15.7) in the n-hexane group.(10) This research  is 
also in line with previous research on human by Harfina, et 
al., which showed that Puguntano leaf,  Simplicia powders, 
had an effect in lowering blood sugar levels in patients with 
diabetes mellitus at dose of 2 gram 3 times a day,  for  14 
days,  if  given  orally  in  the  form  of  steeping.(8,10)
  Metformin is one of oral hypoglycemic drug that 
has primary effect of reducing the production of liver 
glucose (gluconeogenesis) as well as improving peripheral 
glucose uptake. The efficacy, safety, and beneficial effects 
of cardiovascular and metabolic make metformin the first 
choice agent in recent years to lower glucose in the treatment 
of T2DM patients.(11)
 Previous study has found that Puguntano plants contain 
glycosides, flavonoids, tannins and steroids/triterpenoids.
(7) This is also accordance to the finding of Puguntano 
leaf ethanol extract obtained by percolation and socletation 
methods contained the same phytochemical content of 
flavonoids, saponins, tannins, glycosides and steroids/
terpenoids. Chemical compounds that responsible for anti-
inflammatory effects is steroids/triterpenoids. The anti-
inflammatory effects of steroid/triterpenoids are related to 
their ability to inhibit the enzymatic action of phospholipase, 
thus preventing the release of mediators of inflammatory 
processes, arachidonic acid and its metabolites, such as 
prostaglandin, leukotrien, thromboxane and prostacyclin, so 
further inflammation can be avoided. 
 From this study we can found that Puguntano extract 
is able to reduce hyperglycemia in T2DM patients. Its 
effect also was not much different from metformin which 
has become the first line standard drugs in the treatment 
of T2DM. In this study, hs-CRP level in both groups were 
decreased, although the result was not statistically significant. 
Steroid/triterpenoids in Puguntano extract act as an anti-
inflammatory, thereby reducing the inflammatory response. 
The decrease in hs-CRP level occurring in Puguntano group 
was also thought due to the improved blood sugar control 
in subjects before and after treatment, and this might be 
influenced by the content of other chemical compounds in 
Puguntano beside steroid/triterpenoids.
 While in the metformin group, the finding is consistent 
with the positive effect of metformin on inflammation 
markers in patients with impaired glucose tolerance. 
In a previous study  conducted  by Chakraborty, et al., a 
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significant reduction in serum CRP concentrations was 
also  observed  after  metformin  therapy.(17)  Serum  hs-
CRP  levels  of  T2DM  patients  also exhibited  an obvious 
reduction  after  treatment  with  active  metformin.(18)  But 
the above results are different from some previous studies 
that did not find any effect of metformin on hs-CRP levels 
in T2DM patients. A research in Iraq was done in 103 
newly diagnosed T2DM patients (53 patients were given 
metformin and 50 patients were given glibenclamide). 
Subjects receiving metformin showed increasing hs-CRP 
levels from 6.59±3.19 before the treatment and 6.12±2.71 
after treatment. Meanwhile subjects receiving glibenclamide 
showed increasing hs-CRP levels from 4.95±2.71 before the 
treatment and 5.46±2.76 after treatment. The results showed 
no significant hs-CRP results in patients either metformin 
group or glibenclamid group after therapy for 2 month.(12) 
Previous research by De Jager J, et al., found that metformin 
administration did not affect the level of inflammatory 
markers (CRP) in T2DM patients.(13) Subjects receiving 
metformin for 16 weeks showed hs-CRP levels 3.26 (2.80-
3.78) before treatment and 3.34 (2.89-3.86) after treatment.
 This current study showed that effect of Puguntano 
extract on inflammation that supposed to precede and predict 
the pathogenesis of T2DM almost the same as the effect of 
metformin. But this study has few limitations, which are: 
1) a small sample size, hence the possibility of the actual 
results can not be reflected; 2) the activity and daily dietary 
intake of the patients can not be standardized, hence it has 
influenced the measurement results; and 3) the compliance 
level of the samples were not assessed.Conclusion
Puguntano has been observed to decrease hs-CRP levels, 
where it acts as an  indicator of inflammatory process in 
T2DM patients. Eventhough the result was not statistically 
significant, from this research it has been showed that there 
was an effect of Puguntano extract towards hs-CRP level 
in T2DM patients, where hs-CRP level decreases by giving 
Puguntano extract. References
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